Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-541468 randomized placebo-controlled tolerability, PK, and PD study in healthy adults and elderly subjects
NL-OMON42430Active, not recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of daridorexant in Insomnia and sleep disorder (7 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Pharmacokinetics of ACT-541468 in Part A Day 1 and Day 5, Additional pharmacokinetics of ACT-541468 in Part A Day 5 and 8 more. Started Sep 2015; status: active, not recruiting.
02
Drugs
daridorexant
03
Conditions
Insomniasleep disorder
Beyond the preview
Go deeper on NL-OMON42430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42430.